HealthCare Institute of New Jersey Statement on WTO TRIPS Waiver Decision
Trenton, March 2, 2024 ― Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning the World Trade Organization’s decision on expansion of the TRIPS waiver: “The HealthCare Institute of New Jersey (HINJ) applauds the World Trade Organization’s decision not to expand the Trade-Related Aspects […]
HealthCare Institute of New Jersey Statement on Senate HELP Hearing on Lowering Health Care Costs
Trenton, February 8, 2024 ― Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning the Senate HELP Committee’s hearing on lowering health care costs: “As the ‘medicine chest of the world,’ we are enormously proud that New Jersey is home to so many of […]
HealthCare Institute of New Jersey statement on the retirement of President and Chief Executive Officer Dean J. Paranicas
Trenton, December 11, 2023 ― Chris Lepore, Chair of the Board of Trustees of the HealthCare Institute of New Jersey (HINJ) and Vice President, U.S. State Affairs, Johnson & Johnson, released the following statement announcing the retirement of HINJ President and Chief Executive Officer Dean J. Paranicas: “After nearly 13 impactful years as President and […]
Healthcare Institute of New Jersey Statement on First List of Medicines Subject to Government Price Setting
Trenton, August 29, 2023 ― Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning the Administration’s announcement of the first ten prescription medicines subject to government price setting: (Read full statement here)
Opinion: Life Sciences Save More Than Lives
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer. The storied achievements of our life sciences sector – our biopharmaceutical, biotech, diagnostic and medical device companies – are globally known. Since the early twentieth century, they range from the discovery of penicillin to COVID-19 vaccines; the first polio vaccine to the first-ever […]
Government Price-Setting Harms Patients, Prevents Cures
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer Among our many learnings from the COVID-19 pandemic is that a robust and effective medical innovation ecosystem is essential to researching and developing treatments, vaccines and cures for new and emerging threats to human health, as well as finding life-saving innovations for existing, […]
Biggest Need for New Jersey’s STEM Future: Keeping Our Talent Here
An op-ed by Dean J. Paranicas, HINJ President and Chief Executive Officer and Anthony S. Cicatiello, President of the R&D Council of New Jersey …
Rare Disease Day Highlights the Imperative to Support Biomedical Research
About 1 in 11 Americans, and 350 million people worldwide, suffer from a rare disease, defined as a disease affecting less than 200,000 people in the United States. …
Blame Middlemen, Insurers for Prices at the Drug Counter
The Star-Ledger’s recent editorial, “Drug prices are obscene, and (Gov. Phil) Murphy is blocking the smart solution,” left out key facts regarding the role of drug manufacturers in determining what patients pay for name-brand medicines. …
HealthCare Institute of New Jersey Statement on Vital Transformation Report on Price Controls
Trenton, July 29, 2022 ― Dean J. Paranicas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning recent discussions in Washington on potential drug pricing legislation: “A new report by the consultancy Vital Transformation on the impact that price control policies under discussion in Washington would have […]